Evidence map›Paper›PMID 40539058›Full record

ArticleFrontiers in immunology2025

Multidisciplinary analysis of the prognosis and biological function of NUBPL in gastric cancer.

Luqian Liu, Fengyu Zhang, Jiaye Yu, Pingping Dong, Jing Deng, Weiwei Liu, Xinlei Cao, Juanjuan Huang, Xiaoming Lin, Xiangyang Xue

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Luqian Liu *Wenzhou Collaborative Innovation Center of Gastrointestinal Cancer in Basic Research and Precision Medicine, Wenzhou Key Laboratory of Cancer-related Pathogens and Immunity, Department of Microbiology and Immunology, Institute of Molecular Virology and Immunology, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, China.
Fengyu Zhang *School of Biomedical Engineering, Tianjin Medical University, Tianjin, China.
Jiaye Yu *Wenzhou Collaborative Innovation Center of Gastrointestinal Cancer in Basic Research and Precision Medicine, Wenzhou Key Laboratory of Cancer-related Pathogens and Immunity, Department of Microbiology and Immunology, Institute of Molecular Virology and Immunology, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, China.
Pingping DongDepartment of Thoracic Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Jing DengWenzhou Collaborative Innovation Center of Gastrointestinal Cancer in Basic Research and Precision Medicine, Wenzhou Key Laboratory of Cancer-related Pathogens and Immunity, Department of Microbiology and Immunology, Institute of Molecular Virology and Immunology, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, China.
Weiwei LiuWenzhou Collaborative Innovation Center of Gastrointestinal Cancer in Basic Research and Precision Medicine, Wenzhou Key Laboratory of Cancer-related Pathogens and Immunity, Department of Microbiology and Immunology, Institute of Molecular Virology and Immunology, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, China.
Xinlei CaoWenzhou Collaborative Innovation Center of Gastrointestinal Cancer in Basic Research and Precision Medicine, Wenzhou Key Laboratory of Cancer-related Pathogens and Immunity, Department of Microbiology and Immunology, Institute of Molecular Virology and Immunology, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, China.
Juanjuan HuangDepartment of Biomedical Sciences, Faculty of Health Sciences, University of Macau, Taipa, Macao SAR, China.
Xiaoming LinDepartment of Thoracic Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Xiangyang XueWenzhou Collaborative Innovation Center of Gastrointestinal Cancer in Basic Research and Precision Medicine, Wenzhou Key Laboratory of Cancer-related Pathogens and Immunity, Department of Microbiology and Immunology, Institute of Molecular Virology and Immunology, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Researchers are currently concentrating on molecular markers and potential therapeutic targets associated with gastric cancer in light of recent developments in precision medicine and molecular biology. Disulfidptosis was first proposed in 2023 as a novel programmed cell death mode associated with the cytoskeleton. Disulfidptosis-related proteins are essential for the preservation of protein stability and abnormal expression of disulfidptosis-related genes may be linked to cancer development and drug resistance. Materials and method: The gastric cancer transcriptomic data were retrieved from TCGA database, and disulfidptosis-related genes were identified through literature search. Utilizing machine learning methods such as LASSO, Random Forest (RF), Boruta, SVM-RFE, and XGBoost, the disulfidptosis-related gene NUBPL was determined as a potential predictor for gastric cancer. PPI network was constructed, and the GO database as well as the KEGG database were employed to analyze the protein interactions and pathway enrichment of NUBPL in gastric cancer. Meanwhile, the ESTIMATE algorithm was used for immune infiltration analysis and prediction of immunotherapy response, and the Genomics of Drug Sensitivity in Cancer (GDSC) database was utilized for the drug sensitivity analysis of NUBPL. The role of NUBPL in gastric cancer and its inhibition of disulfidptosis were validated using molecular biological methods. Results: The aberrant expression of NUBPL significantly impacts the prognosis of gastric cancer and modulates metabolic and immune-related pathways. In patients with elevated NUBPL expression levels, a reduced number of CD8-positive T cells is associated with adverse prognosis and gastric cancer progression. Elevated NUBPL expression levels can impair the function of chemokines. Moreover, patients with lower NUBPL expression levels exhibit better responses to immunotherapy. We have also identified drugs such as QS11, Imatinib, and AS601245 as potential inhibitors of NUBPL. Conclusion: This study underscores the pivotal role of NUBPL in gastric cancer progression and highlights its significance as a potential target for targeted therapy and immunotherapy gastric cancer, NUBPL, disulfidptosis, biomarker, immunotherapy, machine learning.

Indexed as

Biomarkers, TumorStomach NeoplasmsComputational BiologyDatabases, GeneticGene Expression ProfilingGene Expression Regulation, NeoplasticHumansPrognosisProtein Interaction MapsBiomarkers, Tumorbiomarkerdisulfidptosisgastric cancerimmunotherapymachine learningNUBPL

Identifiers

PMID40539058
PMCPMC12176871

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.